Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams

Jun 4, 2026 · 41 min · YouTube

Ads
5
Brands
3
Inserted
0
Transcript
7k words

Ads in this episode

EP · Huberman Lab · Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams41:08
7:50host read
Function Health
code HUBERMAN
20:22host read
BetterHelp
betterhelp.com/huberman
34:33host read
AG1
mid-roll
35:15host read
AG1
mid-roll
AtBrandTypePlacementPromo codeURLFound by
7:50–9:24Function Healthhost readaudio + YouTubemid-rollHUBERMANfunctionhealth.com/hubermantrigger+chapter
20:22–21:41BetterHelphost readaudio + YouTubemid-rollbetterhelp.com/hubermantrigger+chapter
34:33–35:11AG1host readaudio + YouTubemid-rollchapter+trigger
35:15–35:29AG1host readaudio + YouTubemid-rollchapter+trigger
35:26–36:09AG1host readaudio + YouTubemid-rolldrinkag1.com/hubermanchapter+trigger

Transcript

asr · 6,968 words · docs
0:00Welcome to Huberman Lab Essentials, where we revisit past episodes for the most potent and actionable science-based tools for mental health, physical health, and performance.
0:11I'm Andrew Huberman, and I'm a professor of neurobiology and ophthalmology at Stanford School of Medicine.
0:17And now for my discussion with Dr.
0:19Nolan Williams.
0:20Thanks for joining today.
0:22I'm really excited to have this conversation.
0:24I have a lot of questions about different compounds, psychedelics in particular.
0:30But before we get into that discussion, I want to ask you about depression, broadly speaking.
0:35I heard you say in a wonderful talk that you gave that depression is perhaps the most debilitating condition worldwide.
0:44Yet in contrast to other medical conditions like cancer, we actually have a fairly limited number of tools to approach depression.
0:52And yet the number of tools and the potency of those tools is growing.
0:56Depression is the most disabling condition worldwide.
Full transcripts are coming soon

6,968 words with timestamps and ad segments marked. Join the waitlist for early access.